Quantcast
Last updated on April 17, 2014 at 10:14 EDT

Latest Celgene Stories

2014-04-04 12:27:14

FLINT, Mich., April 4, 2014 /PRNewswire-iReach/ -- Diplomat has announced that it is one of a select group of specialty pharmacies contracted by Celgene to distribute Otezla® (apremilast), a new medication for the treatment of psoriatic arthritis. Otezla® is an oral small-molecule inhibitor of phosphodiesterase 4 (PDE4) specific for cyclic adenosine monophosphate (cAMP). Otezla® was approved by the FDA on March 21, 2014, and is available in 10 mg, 20 mg and 30 mg tablets. Diplomat...

2014-04-03 12:29:29

Poor Efficacy and Physicians' Desire for Personalized Therapeutics Will Provide Opportunity for Developers of New Therapies, According to Findings from Decision Resources Group BURLINGTON, Mass., April 3, 2014 /PRNewswire/ -- Decision Resources Group finds that azacitidine (Celgene's Vidaza, generics) will continue to be the patient share leader in treatment of myelodysplastic syndromes (MDS) in the United States and major European markets during the 2013-2023 study period. According to...

2014-03-27 12:30:26

DUBLIN, Mar. 27, 2014 /PRNewswire/ -- Research and Markets ( http://www.researchandmarkets.com/research/fzv3mt/global ) has announced the addition of the "Global Pharmaceutical & Biotechnology Outlook 2014: Mature Biotech" report to their offering. (Logo: http://photos.prnewswire.com/prnh/20130307/600769) Positive sentiments for the biotech sector have prevailed in the last two to three years, and the authors expect this trend to continue for the next year too. The optimism is based on...

2014-03-26 08:23:02

DUBLIN, Mar. 26, 2014 /PRNewswire/ -- Research and Markets ( http://www.researchandmarkets.com/research/pt8tl4/treating ) has announced the addition of the "Concise Analysis of New Methods for Treating Refractory Hematological Malignancies - Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML)" report to their offering. (Logo: http://photos.prnewswire.com/prnh/20130307/600769) Targeting unmet needs in the treatment of cancer through innovative drug development strategies have...

2014-03-26 08:22:56

DUBLIN, Mar. 26, 2014 /PRNewswire/ -- Research and Markets ( http://www.researchandmarkets.com/research/lnx8jm/treating ) has announced the addition of the "Concise Analysis on Treating Refractory Hematological Malignancies for Multiple Myeloma" report to their offering. (Logo: http://photos.prnewswire.com/prnh/20130307/600769) "Concise Analysis on Treating Refractory Hematological Malignancies for Multiple Myeloma", provides an overview of the therapies for Multiple Myeloma (Newly...

2014-03-24 08:29:41

SAN FRANCISCO, March 24, 2014 /PRNewswire/ -- Sutro Biopharma, a biopharmaceutical company developing a new generation of protein therapeutics, including next-generation antibody drug conjugates and bispecific antibodies, today announced that it will present at the 21(st) Annual Future Leaders in the Biotech Industry Conference taking place on March 28, 2014, at the Millennium Broadway Hotel & Conference Center in New York City. William J. Newell, chief executive officer of...

2014-03-04 08:30:57

SYDNEY, March 4, 2014 /PRNewswire/ -- Novogen Limited (ASX:NRT; NASDAQ:NVGN]), an oncology drug development company, today announced key new appointments to guide the company in its transition into a clinical-stage company with a growing U.S. presence and an investor base in the U.S. and Australia. Professor Peter Gunning, PhD, a leading world authority on the cytoskeleton, and Iain Ross, an experienced multi-national pharmaceutical and biotechnology executive, join the Novogen board...

2014-02-28 08:25:18

SAN DIEGO and PRINCETON, N.J., Feb. 28, 2014 /PRNewswire/ -- Abide Therapeutics today announced it has entered into a strategic collaboration with Celgene Corporation to discover and develop new drugs in inflammation and immunology. Abide has pioneered innovative technologies to selectively target serine hydrolases, one of the largest enzyme families involved in regulating human physiology. (Logo: http://photos.prnewswire.com/prnh/20130502/LA06084LOGO) Under the terms of the...

2014-02-27 16:28:01

-- Advanced EPZ-5676 DOT1L inhibitor program, achieved $25 million proof of concept milestone with Celgene, and initiated Phase 1 study expansion stage for MLL-r and MLL-PTD patients CAMBRIDGE, Mass., Feb. 27, 2014 /PRNewswire/ -- Epizyme, Inc. (NASDAQ: EPZM), a clinical stage biopharmaceutical company creating innovative personalized therapeutics for patients with genetically defined cancers, today announced 2013 operating and financial results and provided 2014 guidance. "2013 was a...

2014-02-26 12:25:05

SHANGHAI, Feb. 26, 2014 /PRNewswire/ -- WuXi PharmaTech (Cayman) Inc. (NYSE: WX), a leading pharmaceutical, biotechnology and medical device R&D outsourcing company with operations in China and the United States, today announced that Dr. Hua Mu has joined WuXi as Senior Vice President of Operations and Global Head of the Product Development Service and Partnership Business Unit, reporting to Dr. Ge Li, Chairman and CEO of WuXi PharmaTech. Dr. Mu has over 18 years of clinical...